Stability Study of Extemporaneous Sildenafil Oral Suspensions

Authors

  • Jiraporn Leanpolchareanchai Department of Pharmacy, Faculty of Pharmacy, Mahidol University
  • Jiraphong Suksiriworapong Department of Pharmacy, Faculty of Pharmacy, Mahidol University
  • Monwarat Laohajeeraphan Pharmacy Department, Siriraj Hospital, Faculty of Medicine Siriraj Hospital
  • Duangjai Chanton Department of Pharmacy, Faculty of Pharmacy, Mahidol University
  • Nanthawan Jinakul Department of Microbiology, Faculty of Pharmacy, Mahidol University

Keywords:

stability, extemporaneous preparations, sildenafil, suspension, generic drug product

Abstract

Background: Sildenafil is used for the treatment of pulmonary arterial hypertension in pediatric patients. In Thailand, sildenafil suspension is currently commercially unavailable.
Objectives: To formulate extemporaneous sildenafil suspensions and investigate their stability.
Method: The sildenafil suspensions at the concentration of 2.5 mg/mL were prepared using 4 different vehicles. The vehicles were divided into 2 groups. The first group contained only 80%w/v syrup with 0.1%w/v sodium benzoate (Rx1) while the other consisted of the mixture of 1.5%w/v CMC mucilage,
80%w/v syrup and purified water at various ratios (Rx2-4) with 0.1%w/v sodium benzoate. All preparations were kept in amber bottles and stored at 2-8°C and 30±2°C/75±5%RH for 120 days.
Results: All formulations, after freshly prepared, possessed light blue uniform suspension and had pH in the range of 4.8-5.6. After storage at both conditions for 120 days, the preparations of Rx2-3 had unchanged appearance and uniformity after redispersion, minimally changed in pH and number
of redispersion and more than 90% of drug remaining. However, the preparation of Rx3 had the better physical characteristics than the preparation of Rx2 after storage in both conditions for 120 days. Hence, the preparation of Rx3 was selected to study the microbiological stability. The results showed that the formulation had no observed colony of bacteria, yeast and mold and Escherichia coli.
Conclusion: The sildenafil suspension prepared from generic drug product using the mixture of 1.5%w/v CMC mucilage and 80%w/v syrup at the ratio 1:1 as a vehicle was physically, chemically and microbiologically stable upon storage at 2-8°C and 30±2°C/75±5%RH for 120 days.

Author Biographies

Jiraporn Leanpolchareanchai, Department of Pharmacy, Faculty of Pharmacy, Mahidol University

B.S. (Pharm), Ph.D. (Pharmaceutics)

Jiraphong Suksiriworapong, Department of Pharmacy, Faculty of Pharmacy, Mahidol University

B.S. (Pharm), Ph.D. (Pharmaceutics)

Monwarat Laohajeeraphan, Pharmacy Department, Siriraj Hospital, Faculty of Medicine Siriraj Hospital

B.S. (Pharm), M. Sc. in Pharm (Clinical Pharmacy)

Duangjai Chanton, Department of Pharmacy, Faculty of Pharmacy, Mahidol University

B.S.

Nanthawan Jinakul, Department of Microbiology, Faculty of Pharmacy, Mahidol University

B.S.

References

Gallié N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353(20):2148-57.

Durongpisitkul K, Pornrattanarungsi S, Panjasamanvong P, Chungsomprasong P. Efficacy and safety of high dose generic sildenafil in Thai patients with pulmonary arterial hypertension. J Med Assoc Thai. 2011;94(4):421-6.

Nahata MC, Morosco RS, Brady MT. Extemporaneous sildenafil citrate oral suspensions for the treatment of pulmonary hypertension in children. Am J Health Syst Pharm. 2006;63(3):254-7.

Sae Yoon A, Sawatdee S, Woradechakul C, Chee KS, Atipairin A. Physicochemical and microbiological stability of the extemporaneous sildenafil citrate oral suspension. Sci Pharm. 2015;83(4):659-70.

The International Conference on Harmonisation (ICH) Committee. ICH Harmonised Tripartite Guideline, Guidance for Industry Q1A(R2) Stability testing of new drug substances and products [Internet]. Geneva: ICH; updated 2003 February 6; [cited 2018 Dec 1]. Available from: https://database.ich.org/sites/default/files/Q1A%28R2%29%20Guideline.pdf.

The United States Pharmacopeial Convention Inc. The United States Pharmacopeia and the National Formulary (USP 41-NF 36). Maryland: The United States Pharmacopoeial Convention; 2017. 8228 p.

The Medicines and Healthcare Products Regulatory Agency. The British Pharmacopoeia Commission. The British Pharmacopoeia 2018. London: The Stationery Office; 2017. 6576 p.

The International Conference on Harmonisation (ICH) Committee. ICH Harmonised Tripartite Guideline, Guidance for Industry Q2(R1) Validation of analytical procedures: Text and methodology [Internet]. Geneva: ICH; updated 2005 November; [cited 2018 Dec 1]. Available from: https://database.ich.org/sites/default/files/Q2_R1__Guideline.pdf.

U.S. Food and Drug Administration (FDA). REVATIO (sildenafil) label [Internet]. Maryland: U.S. FDA; updated 2018 October 10; [cited 2018 Dec 1]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021845s011,022473s004,0203109s002lbl.pdf.

U.S. Food and Drug Administration (FDA). FDA drug safety communication: FDA recommends against use of Revatio (sildenafil) in children with pulmonary hypertension [Internet]. Maryland: U.S. FDA; updated 2017 December 15; [cited 2018 Dec 1]. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm317123.htm.

U.S. Food and Drug Administration (FDA). FDA drug safety communication: FDA clarifies warning about pediatric use of Revatio (sildenafil) for pulmonary arterial hypertension [Internet]. Maryland: U.S. FDA; updated 2016 January 1; [cited 2018 Dec 1]. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm390876.htm.

European Medicines Agency (EMA). Assessment report for Revatio. International non-proprietary name: sildenafil. Procedure No. EMEA/H/C/000638/II/0028 [Internet]. London: EMA; updated 2011; [cited 2018 Dec 1]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000638/WC500107804.pdf.

The Heart Association of Thailand under the Royal Patronage of His Majesty the King. Thai guideline for diagnosis and treatment of pulmonary hypertension 2013. 2nd ed. Bangkok: Colour Harmony Co. Ltd.; 2013. 75 p.

The Paediatric Formulary Committee. British National Formulary for Children (BNFC) 2011–2012. London: The British Medical Association, the Royal Pharmaceutical Society of Great Britain, the Royal College of Paediatrics and Child Health, and the Neonatal and Paediatric Pharmacists Group; 2011. 844 p.

The United States Pharmacopeial Convention Inc. The United States Pharmacopeia and the National Formulary (USP 39-NF 34). Sildenafil compounded oral suspension. Maryland: The United States Pharmacopoeial Convention; 2016. 8228 p.

Downloads

Published

2021-05-25

How to Cite

1.
Leanpolchareanchai J, Suksiriworapong J, Laohajeeraphan M, Chanton D, Jinakul N. Stability Study of Extemporaneous Sildenafil Oral Suspensions. Thai J Hosp Pharm [Internet]. 2021 May 25 [cited 2026 Nov. 23];31(1):1-13. Available from: https://he02.tci-thaijo.org/index.php/TJHP/article/view/250869

Issue

Section

Original Article

Similar Articles